Clinical efficacy and safety of liposomal doxorubicin in treatment of cancer: A systematic review
10.7501/j.issn.1674-6376.2017.09.030
- VernacularTitle:脂质体多柔比星治疗恶性肿瘤临床疗效及安全性的系统评价
- Author:
Yi GUO
1
;
bo Yu LIU
;
Bing CHEN
Author Information
1. 常州金远药业制造有限公司
- Keywords:
liposomal doxorubicin;
liposomal adriamycin;
cancer;
clinical curative effect;
safety evaluation;
Meta-analysis
- From:
Drug Evaluation Research
2017;40(9):1338-1347
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy and safety of liposomal doxorubicin in the treatment of cancer.Methods The randomized controlled trials of liposomal doxorubicin in treatment of cancer were searched from Chinese academic literature database (CNKI),Wanfang digital joumals,Chinese biomedical literature database (CBM),Chinese scientific journal database (VIP),PubMed database,Embase database and The Cochrane Library database.Data were collected from establishment of the database to January 2017 and the each index was analyzed by Meta-analysis with RevMan 5.3 software.Results A total of 5546 patients with malignant tumors were included in the RCT literature of the 23 articles.The Meta analysis results showed that the analysis on clinical curative effect before and after treatment:I2 =63％,OR =1.14[1.02,1.27],P =0.002;the analysis on safety evaluation of Meta of two groups of cardiac toxicity adverse events:I2=0％,OR =0.18[0.10,0.33],P ＜ 0.00001;I2=77％,OR =0.24[0.17,0.35];the analysis on alopecia adverse events:P ＜ 0.000 01;I2=46％ OR=0.65[0.42,0.99],the ananlysis on neurotoxic adverse events:P =0.05.Conclusion The clinical efficacy of liposomal doxorubicin in the treatment of malignant tumors is better than other chemotherapy regimens,with low side effects,and is especially significantly better than other chemotherapy regimens in the improvement of cardiac toxicity,neurotoxicity,alopecia and other adverse events.
